Food and Drug Administration Certain Bulk Drug Substances page lists Selank acetate (TP-7) in the withdrawn nominators table, with the following verbatim safety concern: Compounded drugs containing selank acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation and peptide-related impurities
doi: 10.3389/fimmu.2024.1476859 Received 06 August 2024 Accepted 03 December 2024 Published 19 December 2024 Volume 15 - 2024 Edited by Carmelo Carmona-Rivera, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH), United States Reviewed by Jos Jiram Torres-Ruiz, National Institute of Medical Sciences and Nutrition Salvador Zubirn, Mexico Matteo Doglio, San Raffaele Hospital (IRCCS), Italy Lauren Robinson, Hospital for Special Surgery, United States Updates Copyright 2024 Zhou, Lei, Shi, Luo, Wu, Xu, Zhang, Liu, Wang, Zhou and He
However, glucose supplementation alone does not appear to represent an optimal strategy (Robbins & Swanson, 2014)
2, 7- Dichlorofluorescein diacetate (DCFDA) was from Molecular Probes (Eugene, OR, USA)